Global state: 1. Requiring supplementary medication ‐ antipsychotics · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Clinically important response to treatment (short term) · patients with schizophrenia
Haloperidol showed no clear difference in clinically important response to treatment (short term) compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review
Adverse events as N of participants with at least one adverse event objective · patients with schizophrenia
It is very uncertain whether haloperidol changes adverse effects: number of participants with at least one adverse… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (medium term) · patients with schizophrenia
It is very uncertain whether haloperidol changes adverse effects: extrapyramidal side effects: number of participants… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia
It is very uncertain whether haloperidol changes leaving the study early due to adverse events as a measure of… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with schizophrenia
Haloperidol showed no clear difference in adverse effects: number of participants with at least one adverse… compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether haloperidol changes adverse effects: extrapyramidal side effects: number of participants… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Response to treatment (medium term) Clinically important response to treatment as defined by each study · patients with schizophrenia
Haloperidol may leads to lower clinically important response to treatment (medium term) compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review
Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia
It is very uncertain whether haloperidol changes leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with schizophrenia
1 finding from 1 review
No improvement (clozapine vs olanzapine) · people with psychosis
1 finding from 1 review
Drug‐induced diabetes (clozapine vs olanzapine) · people with psychosis
1 finding from 1 review
Elevated prolactin (risperidone vs quetiapine) · people with psychosis
1 finding from 1 review
Weight gain · people with psychosis
1 finding from 1 review
Leaving the study early because of weight gain (risperidone vs olanzapine) · people with psychosis
1 finding from 1 review
No response · people with psychosis
1 finding from 1 review
Symptomatic hyperprolactinaemia · people with psychosis
1 finding from 1 review
Use of antiparkinsonian medications · people with psychosis
1 finding from 1 review